Lab Genetic Fraud Whistleblower: False Claims Act Guide

When Federal Health-Care Fraud Enforcement Reaches the Laboratory: An Introduction for Potential Whistleblowers

Federal prosecutors pursue a wide range of health-care fraud schemes with significant resources and resolve. A recent Massachusetts case illustrates how seriously authorities treat fraud that harms patients and misuses the health-care system: a med spa owner was sentenced to 46 months in prison for performing more than 2,700 procedures using counterfeit injectable products on more than 900 clients. That case involved counterfeit cosmetic injections, not genetic testing — but it reflects the same prosecutorial seriousness that federal authorities bring to lab genetic fraud whistleblower matters involving Medicare and Medicaid.

Laboratory genetic fraud is a distinct area of federal enforcement concern. These schemes typically involve clinical or reference laboratories submitting false claims to federal health-care programs for genetic tests that were medically unnecessary, never ordered by a treating physician, or obtained through illegal kickback arrangements. The underlying enforcement mechanism — the False Claims Act — operates across health-care fraud categories, including genetic testing fraud. This article explains what lab genetic fraud typically involves, how the False Claims Act applies, and what a potential whistleblower should consider before coming forward.

What Lab Genetic Fraud Typically Involves

Lab genetic fraud schemes generally involve laboratories submitting claims to Medicare or Medicaid for genetic tests that were not medically necessary, were never ordered by a treating physician, or were procured through illegal financial arrangements. Because Medicare and Medicaid are federal programs, false claims submitted to them can trigger federal liability.

Common patterns in this area of enforcement include:

• Billing for genetic panels not ordered by a treating physician. A laboratory may submit claims for comprehensive genetic panels — such as cancer screening or pharmacogenomics panels — when no physician with an ongoing treatment relationship actually ordered the test for the patient.
• Cheek-swab marketing campaigns and illegal specimen referrals. Some schemes involve paying marketers or recruiters to solicit Medicare or Medicaid beneficiaries — often through health fairs, telemarketing, or door-to-door outreach — to submit cheek-swab specimens, with payments made in exchange for those referrals in violation of federal anti-kickback principles.
• Upcoding genetic panel results. A laboratory may bill for a higher-reimbursement genetic test code than the test actually performed, inflating the amount claimed from federal health-care programs.

Each of these patterns, when it results in a false or fraudulent claim submitted to a federal program, may give rise to liability under the False Claims Act. Individuals with direct knowledge of such conduct may have the ability to bring that information to federal authorities through the Act’s qui tam provisions.

How the False Claims Act Creates a Path for Lab Genetic Fraud Whistleblowers

Under 31 U.S.C. § 3730(b), a person may bring a civil action for a violation of section 3729 for the person and for the United States Government. This qui tam mechanism allows a private individual — called a “relator” — to file suit on the government’s behalf, placing laboratory fraud under the False Claims Act within reach of employees, billing staff, compliance officers, and others who have direct and independent knowledge of the alleged misconduct.

The financial stakes for relators can be significant. Under 31 U.S.C. § 3730(d), the statute provides for the following relator shares:

• When the government intervenes: the relator may receive at least 15 percent but not more than 25 percent of the proceeds of the action or settlement, depending upon the extent to which the person substantially contributed to the prosecution of the action — subject to the proviso that where the action is based primarily on disclosures of specific information other than information provided by the person, the court may award no more than 10 percent of such proceeds.
• When the government does not intervene: the relator may receive an amount the court decides is reasonable, but in no case more than 30 percent of the proceeds.

These figures represent what the statute provides; they do not assure any particular recovery in any individual case.

The False Claims Act also provides meaningful protection for employees who face retaliation for reporting fraud. Under 31 U.S.C. § 3730(h), any employee, contractor, or agent who is discharged, demoted, suspended, threatened, harassed, or in any other manner discriminated against in the terms and conditions of employment because of lawful acts done in furtherance of a False Claims Act action or other efforts to stop a violation shall be entitled to all relief necessary to make that employee, contractor, or agent whole — including reinstatement, two times the amount of back pay, interest on back pay, and compensation for any special damages sustained.

Individuals who may have standing to bring a lab genetic fraud qui tam action include current or former laboratory employees, billing and coding staff, compliance officers, sales representatives who participated in specimen-referral programs, and others with direct knowledge of the alleged conduct.

What a Potential Whistleblower in a Lab Genetic Case Should Consider Before Coming Forward

Before taking any action, a potential lab genetic fraud whistleblower should consult with attorneys who handle False Claims Act qui tam matters — ideally before disclosing information to colleagues, supervisors, or anyone outside a privileged legal relationship. Early consultation can help preserve important procedural rights and avoid missteps that could affect the viability of a claim.

The Seal Requirement

Under 31 U.S.C. § 3730(b), a qui tam complaint is filed under seal, meaning the defendant is not notified while the government investigates the allegations. The complaint remains under seal for at least 60 days and may remain sealed for a longer period upon the government’s motion. This confidential period allows federal investigators to evaluate the relator’s information without alerting the target of the investigation.

The First-to-File Rule

Timing matters in qui tam cases. Under 31 U.S.C. § 3730(b)(5), when a person brings an action under the qui tam provisions, no person other than the Government may intervene or bring a related action based on the facts underlying the pending action. This means that if another relator has already filed a complaint covering the same conduct, a later-filed complaint based on those same facts may be barred. A potential whistleblower who delays could lose the ability to participate in any recovery.

What to Bring to an Initial Consultation

Attorneys who handle qui tam matters will generally want to understand the nature and scope of the alleged fraud, the relator’s connection to the conduct, and the types of documentation or records that may be available. A potential whistleblower should not remove documents from an employer’s systems without legal guidance, as doing so could create separate legal exposure. The focus of an initial consultation is typically on evaluating whether the information the potential relator holds is direct, independent, and sufficient to support a claim — not on assembling a complete evidentiary record before speaking with counsel.

If practices like these look familiar from your own workplace, you can discuss what you have seen with a Price Armstrong attorney confidentially and at no cost. Call (888) 670-9542 or use the secure evaluation form below.

If practices like these look familiar from your own workplace, you can discuss what you have seen with a Price Armstrong attorney confidentially and at no cost. Call (888) 670-9542 or use the secure evaluation form below.

Frequently Asked Questions

Who can be a whistleblower in a lab genetic fraud case?

Under 31 U.S.C. § 3730(b), a person may bring a qui tam civil action for a violation of section 3729 for the person and for the United States Government. Current or former laboratory employees, billing staff, compliance officers, sales representatives, and others with direct and independent knowledge of alleged false claims submitted to Medicare or Medicaid could potentially qualify as relators — though whether any particular individual’s information supports a viable claim is a question attorneys who handle these matters can evaluate.

What retaliation protections does the False Claims Act provide?

Under 31 U.S.C. § 3730(h), an employee, contractor, or agent who is discharged, demoted, suspended, threatened, harassed, or otherwise discriminated against because of lawful acts in furtherance of a False Claims Act action shall be entitled to all relief necessary to make that person whole, including reinstatement, two times the amount of back pay, interest on back pay, and compensation for special damages. These protections may apply even if the underlying qui tam action does not ultimately succeed.

How much could a relator receive in a lab genetic fraud case?

The False Claims Act provides for a relator share of at least 15 percent but not more than 25 percent of the proceeds when the government intervenes, and an amount the court decides is reasonable but not more than 30 percent when the government does not intervene, subject to the conditions and limitations set out in 31 U.S.C. § 3730(d). No assurance of any particular recovery can be given; the actual share in any case depends on the specific facts, the extent of the relator’s contribution, and the outcome of the litigation or settlement.